Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.
- Published In:
- Molecular therapy. Oncology, 34(1), 201138 (2026)
- Database ID:
- RPEP-15673
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15673APA
Mashayekhi, Kazem; Rahnama, Maryam; Rahman, Md Saidur; Prasad, Anisha; Islam, Shahidul M. (2026). Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.. Molecular therapy. Oncology, 34(1), 201138. https://doi.org/10.1016/j.omton.2026.201138
MLA
Mashayekhi, Kazem, et al. "Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.." Molecular therapy. Oncology, 2026. https://doi.org/10.1016/j.omton.2026.201138
RethinkPeptides
RethinkPeptides Research Database. "Targeted biologics for TNBC: Advances in nanobodies, antibod..." RPEP-15673. Retrieved from https://rethinkpeptides.com/research/mashayekhi-2026-targeted-biologics-for-tnbc
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.